What happened to the gene edited babies in China?

Gene-Edited Babies: The Controversial Return of Scientist He Jiankui

He Jiankui, a Chinese scientist who shocked the world by announcing the creation of the first gene-edited babies, has one of the most fascinating stories in the field of genetic engineering. It has also sparked a great deal of debate. By blocking the CCR5 gene, which serves as a portal for HIV to enter cells, He hoped to immunize the infants against the HIV virus using the ground-breaking CRISPR technology. Even with the work’s significant ramifications, thorough documentation of this accomplishment is still hard to come by.

A Bold Experiment and Its Aftermath

He Jiankui’s foray into human embryo editing was met with a maelstrom of ethical questions and widespread condemnation from the global scientific community. The audacity of manipulating the genetic fabric of human embryos—to potentially alter the course of human evolution—pushed the boundaries of biotechnology and ethics alike. In December 2019, a Chinese court found He guilty of unethical practices, sentencing him to three years in prison and imposing a hefty three-million-yuan fine. His research activities were halted, and he was dismissed from his position at the Southern University of Science and Technology (SUSTech) in early 2019.

Turning Over a New Leaf

Following his release in April 2022, He Jiankui has made a surprising return to the scientific arena. Now, shifting his focus from the contentious field of human embryo editing to less controversial areas, He expresses a renewed dedication to advancing gene therapy. His current ambitions are directed toward combating rare genetic diseases, such as Duchenne muscular dystrophy, and working on the treatment of Alzheimer’s among other genetic disorders. In interviews, He has voiced pride in his past work, despite the jail time and the controversy it sparked. According to reports from the South China Morning Post, he asserts that the three children born from his gene-editing experiment are thriving.

The Way Ahead

He Jiankui’s comeback is not without its challenges. The scientific community and regulatory bodies are observing closely, given the profound ethical implications and the potential for unforeseen consequences associated with gene editing. His pivot to tackling rare diseases through gene therapy, while less controversial, still navigates the complex interplay between ethics, science, and the future of human health.

He Jiankui’s story serves as a pivotal chapter in the ongoing narrative of genetic engineering a testament to the incredible potential and peril of wielding such power. As science advances, so too does the need for rigorous ethical oversight to ensure that the quest for knowledge benefits humanity without compromising the very essence of what it means to be human.

He Jiankui’s story emphasizes the vital significance of ethical vigilance and the collective responsibility to negotiate the tricky moral terrain of genetic innovation in an era where scientific boundaries are constantly being pushed. The lessons from this episode will surely influence the future of genetic engineering and its place in society as we stand on the cusp of a new era in medicine.

References:

Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203:35–40. doi: 10.1084/jem.20051970. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Guttinger S. Trust in Science: CRISPR-Cas9 and the Ban on Human Germline Editing. Sci Eng Ethics. 2018;24:1077–1096. doi: 10.1007/s11948-017-9931-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Gyngell C, Douglas T, Savulescu J. The Ethics of Germline Gene Editing. J Appl Philos. 2017;34:498–513. doi: 10.1111/japp.12249. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

McConnell T. Genetic enhancement, human nature, and rights. J Med Philos. 2010;35:415–428. doi: 10.1093/jmp/jhq034. [PubMed] [CrossRef] [Google Scholar]

Mehlman M, Botkin J. Access to the Genome: The Challenge to Equality. Washington, D.C.: Georgetown University Press; 1998. [Google Scholar]

Share on Facebook

Tweet